A phase Ib/II study of second-line therapy with panitumumab, irinotecan, and everolimus (PIE) in metastatic colorectal cancer with KRAS wild type (WT).

被引：0
作者：
Townsend, A. R.
Pirc, L.
Hardingham, J.
Karapetis, C. S.
Tebbutt, N. C.
Singhal, N.
Price, T. J.
机构：
[1] Queen Elizabeth Hosp, Adelaide, SA, Australia
[2] Basil Hetzel Inst, Adelaide, SA, Australia
[3] Flinders Med Ctr, Adelaide, SA, Australia
[4] Austin Hosp, Ludwig Oncol Unit, Heidelberg, Vic 3084, Australia
[5] Royal Adelaide Hosp, Adelaide, SA 5000, Australia
[6] Queen Elizabeth Hosp, Woodville, SA 5011, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.tps162
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS162
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase II study of panitumumab with irinotecan for patients with KRAS wild-type metastatic colorectal cancer (MCRC) refractory to standard chemotherapy: A GERCOR study
    Chibaudel, B.
    Tournigand, C.
    Mabro, M.
    Bennamoun, M.
    Artru, P.
    Nguyen, S.
    Bachet, J.
    Aissat, N.
    Blons, H.
    Laurent-Puig, P.
    De Gramont, A.
    Andre, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [22] SPIRITT (study 20060141): A randomized phase II study of FOLFIRI with either panitumumab (pmab) or bevacizumab (bev) as second-line treatment (tx) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC)
    Cohn, Allen Lee
    Hecht, J. Randolph
    Dakhil, Shaker
    Saleh, Mansoor N.
    Piperdi, Bilal
    Cline-Burkhardt, Vivian Jean M.
    Tian, Ying
    Go, William Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [23] Phase II Study of Panitumumab With Irinotecan for Patients With KRas Wild-type Metastatic Colorectal Cancer (MCRC) Refractory to Standard Chemotherapy - a GERCor Study
    Andre, T.
    Chibaudel, B.
    Mabro, M.
    Bennamoun, M.
    Artru, P.
    Bachet, J. B.
    Hadengue, A.
    Blons, H.
    Laurent-Puig, P.
    de Gramont, A.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S435 - S435
  • [24] Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer
    Van Cutsem, Eric
    Eng, Cathy
    Nowara, Elzbieta
    Swieboda-Sadlej, Anna
    Tebbutt, Niall C.
    Mitchell, Edith
    Davidenko, Irina
    Stephenson, Joe
    Elez, Elena
    Prenen, Hans
    Deng, Hongjie
    Tang, Rui
    McCaffery, Ian
    Oliner, Kelly S.
    Chen, Lisa
    Gansert, Jennifer
    Loh, Elwyn
    Smethurst, Dominic
    Tabernero, Josep
    CLINICAL CANCER RESEARCH, 2014, 20 (16) : 4240 - 4250
  • [25] PHASE II STUDY OF IRINOTECAN PLUS CETUXIMAB FOR PRETREATED METASTATIC COLORECTAL CANCER WITH KRAS WILD TYPE
    Shitara, Kohei
    Yokota, Tomoya
    Takahari, Daisuke
    Ura, Takashi
    Inaba, Yoshitaka
    Yamaura, Hidekazu
    Sato, Yozo
    Najima, Mina
    Kawai, Hiroki
    Tajika, Masahiro
    Sawaki, Akira
    Yatabe, Yasushi
    Utsunomiya, Setsuo
    Muro, Kei
    ANNALS OF ONCOLOGY, 2010, 21 : 13 - 13
  • [26] Phase II study of panitumumab plus irinotecan as second-line therapy for advanced esophageal adenocarcinoma
    Liu, Yang
    Zaidi, Ali H.
    Nason, Katie S.
    Egloff, Ann M.
    Ferris, Robert
    Jobe, Blair
    Yoon, Harry
    Forastiere, Arlene A.
    Gibson, Michael K.
    CANCER RESEARCH, 2012, 72
  • [27] Comparison of Panitumumab Plus Irinotecan and Cetuximab Plus Irinotecan for KRAS Wild-type Metastatic Colorectal Cancer
    Yamaguchi, Toshifumi
    Iwasa, Satoru
    Nagashima, Kengo
    Ikezawa, Nobuaki
    Hamaguchi, Tetsuya
    Shoji, Hirokazu
    Honma, Yoshitaka
    Takashima, Atsuo
    Okita, Natsuko
    Kato, Ken
    Yamada, Yasuhide
    Shimada, Yasuhiro
    ANTICANCER RESEARCH, 2016, 36 (07) : 3531 - 3536
  • [28] Panitumumab in combination with irinotecan plus S-1 (IRIS) as second-line therapy for metastatic colorectal cancer
    Takaoka, Toshi
    Kimura, Tetsuo
    Shimoyama, Rai
    Kawamoto, Shunji
    Sakamoto, Kazuki
    Goda, Fuminori
    Miyamoto, Hiroshi
    Negoro, Yuji
    Tsuji, Akihito
    Yoshizaki, Koji
    Goji, Takahiro
    Kitamura, Shinji
    Yano, Hiromi
    Okamoto, Koichi
    Kimura, Masako
    Okahisa, Toshiya
    Muguruma, Naoki
    Niitsu, Yoshiro
    Takayama, Tetsuji
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (02) : 397 - 403
  • [29] Panitumumab in combination with irinotecan plus S-1 (IRIS) as second-line therapy for metastatic colorectal cancer
    Toshi Takaoka
    Tetsuo Kimura
    Rai Shimoyama
    Shunji Kawamoto
    Kazuki Sakamoto
    Fuminori Goda
    Hiroshi Miyamoto
    Yuji Negoro
    Akihito Tsuji
    Koji Yoshizaki
    Takahiro Goji
    Shinji Kitamura
    Hiromi Yano
    Koichi Okamoto
    Masako Kimura
    Toshiya Okahisa
    Naoki Muguruma
    Yoshiro Niitsu
    Tetsuji Takayama
    Cancer Chemotherapy and Pharmacology, 2016, 78 : 397 - 403
  • [30] Panitumumab (Pmab) versus cetuximab (Cmab)/irinotecan (Iri) therapy among patients with KRAS wild-type (wt) metastatic colorectal cancer (MCRC).
    Kennecke, Hagen F.
    Chen, Leo
    Blanke, C. D.
    Cheung, Winson Y.
    Schaff, Kimberly
    Speers, Caroline
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
12345